Annual Current Liabilities
$3.55 B
+$805.30 M+29.37%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual total current liabilities is currently $3.55 billion, with the most recent change of +$805.30 million (+29.37%) on 31 December 2023. During the last 3 years, it has risen by +$1.67 billion (+88.94%). VRTX annual current liabilities is now at all-time high.VRTX Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$3.97 B
+$425.90 M+12.01%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly total current liabilities is currently $3.97 billion, with the most recent change of +$425.90 million (+12.01%) on 30 September 2024. Over the past year, it has increased by +$373.70 million (+10.38%). VRTX quarterly current liabilities is now at all-time high.VRTX Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +29.4% | +10.4% |
| 3 y3 years | +88.9% | +107.5% |
| 5 y5 years | +216.7% | +186.1% |
VRTX Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +88.9% | at high | +107.5% |
| 5 y | 5 years | at high | +216.7% | at high | +197.7% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.97 B(+12.0%) |
| June 2024 | - | $3.55 B(-6.6%) |
| Mar 2024 | - | $3.80 B(+7.0%) |
| Dec 2023 | $3.55 B(+29.4%) | $3.55 B(-1.4%) |
| Sept 2023 | - | $3.60 B(+7.4%) |
| June 2023 | - | $3.35 B(+10.8%) |
| Mar 2023 | - | $3.03 B(+10.4%) |
| Dec 2022 | $2.74 B(+28.0%) | $2.74 B(+5.1%) |
| Sept 2022 | - | $2.61 B(+2.1%) |
| June 2022 | - | $2.56 B(+17.2%) |
| Mar 2022 | - | $2.18 B(+1.8%) |
| Dec 2021 | $2.14 B(+14.1%) | $2.14 B(+11.9%) |
| Sept 2021 | - | $1.91 B(+4.2%) |
| June 2021 | - | $1.84 B(-5.5%) |
| Mar 2021 | - | $1.94 B(+3.5%) |
| Dec 2020 | $1.88 B(+40.7%) | $1.88 B(-6.3%) |
| Sept 2020 | - | $2.00 B(+11.4%) |
| June 2020 | - | $1.80 B(+16.9%) |
| Mar 2020 | - | $1.54 B(+15.3%) |
| Dec 2019 | $1.33 B(+19.1%) | $1.33 B(-3.9%) |
| Sept 2019 | - | $1.39 B(+10.3%) |
| June 2019 | - | $1.26 B(+13.8%) |
| Mar 2019 | - | $1.11 B(-1.2%) |
| Dec 2018 | $1.12 B(+38.8%) | $1.12 B(+12.9%) |
| Sept 2018 | - | $992.51 M(+7.0%) |
| June 2018 | - | $927.30 M(+12.1%) |
| Mar 2018 | - | $827.31 M(+2.5%) |
| Dec 2017 | $807.26 M(+1.9%) | $807.26 M(+13.6%) |
| Sept 2017 | - | $710.74 M(+13.6%) |
| June 2017 | - | $625.41 M(+27.7%) |
| Mar 2017 | - | $489.80 M(-38.2%) |
| Dec 2016 | $792.54 M(+56.6%) | $792.54 M(+9.6%) |
| Sept 2016 | - | $722.84 M(+16.1%) |
| June 2016 | - | $622.86 M(+12.8%) |
| Mar 2016 | - | $552.04 M(+9.1%) |
| Dec 2015 | $506.17 M(+37.5%) | $506.17 M(+35.0%) |
| Sept 2015 | - | $374.96 M(+0.3%) |
| June 2015 | - | $373.82 M(+23.6%) |
| Mar 2015 | - | $302.44 M(-17.9%) |
| Dec 2014 | $368.25 M(-7.4%) | $368.25 M(-1.1%) |
| Sept 2014 | - | $372.18 M(+2.5%) |
| June 2014 | - | $362.97 M(-2.8%) |
| Mar 2014 | - | $373.50 M(-6.1%) |
| Dec 2013 | $397.83 M(-8.0%) | $397.83 M(-2.8%) |
| Sept 2013 | - | $409.50 M(+7.3%) |
| June 2013 | - | $381.65 M(-6.4%) |
| Mar 2013 | - | $407.64 M(-5.8%) |
| Dec 2012 | $432.62 M(+10.3%) | $432.62 M(+6.4%) |
| Sept 2012 | - | $406.73 M(+7.1%) |
| June 2012 | - | $379.71 M(+6.4%) |
| Mar 2012 | - | $356.81 M(-9.1%) |
| Dec 2011 | $392.35 M(-17.4%) | $392.35 M(-28.5%) |
| Sept 2011 | - | $548.95 M(+14.6%) |
| June 2011 | - | $478.97 M(+15.1%) |
| Mar 2011 | - | $416.19 M(-12.3%) |
| Dec 2010 | $474.78 M(+66.7%) | $474.78 M(+52.4%) |
| Sept 2010 | - | $311.57 M(+6.6%) |
| June 2010 | - | $292.38 M(+38.2%) |
| Mar 2010 | - | $211.54 M(-25.7%) |
| Dec 2009 | $284.88 M(+31.5%) | $284.88 M(+23.1%) |
| Sept 2009 | - | $231.37 M(+26.0%) |
| June 2009 | - | $183.68 M(+2.4%) |
| Mar 2009 | - | $179.30 M(-17.2%) |
| Dec 2008 | $216.56 M(+8.7%) | $216.56 M(+20.0%) |
| Sept 2008 | - | $180.46 M(-1.3%) |
| June 2008 | - | $182.89 M(+5.5%) |
| Mar 2008 | - | $173.32 M(-13.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $199.28 M(-20.6%) | $199.28 M(+7.3%) |
| Sept 2007 | - | $185.71 M(-8.5%) |
| June 2007 | - | $202.90 M(+16.2%) |
| Mar 2007 | - | $174.59 M(-30.4%) |
| Dec 2006 | $251.01 M(+150.4%) | $251.01 M(+55.5%) |
| Sept 2006 | - | $161.46 M(+48.5%) |
| June 2006 | - | $108.73 M(+32.2%) |
| Mar 2006 | - | $82.24 M(-18.0%) |
| Dec 2005 | $100.24 M(-34.8%) | $100.24 M(-17.7%) |
| Sept 2005 | - | $121.81 M(-11.7%) |
| June 2005 | - | $137.99 M(-6.9%) |
| Mar 2005 | - | $148.17 M(-3.6%) |
| Dec 2004 | $153.75 M(+10.6%) | $153.75 M(+14.4%) |
| Sept 2004 | - | $134.45 M(-2.2%) |
| June 2004 | - | $137.45 M(+13.7%) |
| Mar 2004 | - | $120.84 M(-13.1%) |
| Dec 2003 | $139.07 M(+115.3%) | $139.07 M(+16.1%) |
| Sept 2003 | - | $119.83 M(+38.5%) |
| June 2003 | - | $86.52 M(+53.7%) |
| Mar 2003 | - | $56.29 M(-12.9%) |
| Dec 2002 | $64.60 M(-29.4%) | $64.60 M(+9.9%) |
| Sept 2002 | - | $58.79 M(-5.6%) |
| June 2002 | - | $62.29 M(-5.0%) |
| Mar 2002 | - | $65.55 M(-28.4%) |
| Dec 2001 | $91.55 M(+31.1%) | $91.55 M(-0.4%) |
| Sept 2001 | - | $91.90 M(+136.5%) |
| June 2001 | - | $38.85 M(+21.9%) |
| Mar 2001 | - | $31.87 M(-54.4%) |
| Dec 2000 | $69.86 M(+277.2%) | $69.86 M(-65.0%) |
| Sept 2000 | - | $199.84 M(+712.6%) |
| June 2000 | - | $24.59 M(+53.3%) |
| Mar 2000 | - | $16.04 M(-13.4%) |
| Dec 1999 | $18.52 M(+41.4%) | $18.52 M(+41.4%) |
| Sept 1999 | - | $13.10 M(-7.7%) |
| June 1999 | - | $14.20 M(+2.9%) |
| Mar 1999 | - | $13.80 M(+5.3%) |
| Dec 1998 | $13.10 M(-4.4%) | $13.10 M(+17.0%) |
| Sept 1998 | - | $11.20 M(+28.7%) |
| June 1998 | - | $8.70 M(0.0%) |
| Mar 1998 | - | $8.70 M(-36.5%) |
| Dec 1997 | $13.70 M(+93.0%) | $13.70 M(+16.1%) |
| Sept 1997 | - | $11.80 M(+26.9%) |
| June 1997 | - | $9.30 M(+2.2%) |
| Mar 1997 | - | $9.10 M(+28.2%) |
| Dec 1996 | $7.10 M(-19.3%) | $7.10 M(+31.5%) |
| Sept 1996 | - | $5.40 M(-28.0%) |
| June 1996 | - | $7.50 M(0.0%) |
| Mar 1996 | - | $7.50 M(-14.8%) |
| Dec 1995 | $8.80 M(+46.7%) | $8.80 M(+12.8%) |
| Sept 1995 | - | $7.80 M(-10.3%) |
| June 1995 | - | $8.70 M(+47.5%) |
| Mar 1995 | - | $5.90 M(-1.7%) |
| Dec 1994 | $6.00 M(-17.8%) | $6.00 M(-18.9%) |
| Sept 1994 | - | $7.40 M(+7.2%) |
| June 1994 | - | $6.90 M(+23.2%) |
| Mar 1994 | - | $5.60 M(-23.3%) |
| Dec 1993 | $7.30 M(+87.2%) | $7.30 M(+17.7%) |
| Sept 1993 | - | $6.20 M(+34.8%) |
| June 1993 | - | $4.60 M(-2.1%) |
| Mar 1993 | - | $4.70 M(+20.5%) |
| Dec 1992 | $3.90 M(+44.4%) | $3.90 M(+21.9%) |
| Sept 1992 | - | $3.20 M(+10.3%) |
| June 1992 | - | $2.90 M(+11.5%) |
| Mar 1992 | - | $2.60 M(-3.7%) |
| Dec 1991 | $2.70 M(+68.8%) | $2.70 M(+17.4%) |
| Sept 1991 | - | $2.30 M(+4.5%) |
| June 1991 | - | $2.20 M(+37.5%) |
| Dec 1990 | $1.60 M | $1.60 M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total current liabilities?
- What is the all time high annual current liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual current liabilities year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly current liabilities year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total current liabilities?
The current annual current liabilities of VRTX is $3.55 B
What is the all time high annual current liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total current liabilities is $3.55 B
What is Vertex Pharmaceuticals Incorporated annual current liabilities year-on-year change?
Over the past year, VRTX annual total current liabilities has changed by +$805.30 M (+29.37%)
What is Vertex Pharmaceuticals Incorporated quarterly total current liabilities?
The current quarterly current liabilities of VRTX is $3.97 B
What is the all time high quarterly current liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total current liabilities is $3.97 B
What is Vertex Pharmaceuticals Incorporated quarterly current liabilities year-on-year change?
Over the past year, VRTX quarterly total current liabilities has changed by +$373.70 M (+10.38%)